San Francisco - Two large phase III studies involving 15 percent azelaic gel (Finacea) for the treatment of rosacea each resulted in more than a 50-percent reduction in the number of lesions.
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Deep Histological Margins Do Not Increase cSCC Recurrence Risk if Tumor is Fully Excised
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
Latex Gloves and the Americans With Disabilities Act
Live From Chicago: Bringing Sun Protection Awareness to Communities